secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2026-08-14T11:50:16+00:00
Accession:  0001193125-26-350425
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA Q2 2026: cash $1.0M, R&D up to $6.6M, $50M credit facility extends runway to 2028
--------------------------------------------------------------------------------

- Cash and equivalents $1.0M at June 30, 2026; $5.7M drawn on $50M Parkview credit facility to date.
- R&D expenses $6.6M in Q2 2026 vs $4.9M in Q2 2025; G&A $2.1M vs $1.9M.
- Net operating cash outflow -$13.0M for H1 2026 vs -$10.9M in H1 2025; financing inflows $10.6M.
- Filed IND for TBS-2025 VISTA antibody in AML; expect Phase 1b/2 initiation 2H 2026 and orphan drug designations.
- $50M credit facility from largest shareholder at 12% interest, maturity 2031, extends cash runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/0001193125-26-350425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer